The inferior outcome for MLL-r infant-ALL appears not to be due to differences in drug metabolism and/or toxicity in infants since MLL wild-type (MLLwt) infant-ALL has excellent EFS (74–93%)1,17. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.